Author: Smola, A.; Samadzadeh, S.; Müller, L.; Adams, O.; Homey, B.; Albrecht, P.; Meller, S.
Title: Omalizumab prevents anaphylactoid reactions to mRNA COVIDâ€19 vaccine Cord-id: uaf5u674 Document date: 2021_8_10
ID: uaf5u674
Snippet: Within the first days of initiating mass vaccination with the novel Covid-19 vaccines several anaphylactic reactions have been reported1 . We present two cases experiencing angioedema with or without urticarial rash after the first dose of the mRNA-1273 vaccine. Both patients tolerated the second vaccination after a pre-treatment with the anti-IgE antibody omalizumab.
Document: Within the first days of initiating mass vaccination with the novel Covid-19 vaccines several anaphylactic reactions have been reported1 . We present two cases experiencing angioedema with or without urticarial rash after the first dose of the mRNA-1273 vaccine. Both patients tolerated the second vaccination after a pre-treatment with the anti-IgE antibody omalizumab.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date